Lantheus To Acquire Evergreen Theragnostics
Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical Portfolio
Lantheus Holdings, Inc. (NASDAQ:LNTH) agreed to acquire Evergreen Theragnostics, Inc. in an all-cash transaction involving an upfront payment of $250 million and up to an additional $752.5 million in potential milestone payments.
Lantheus is acquiring radiopharmaceutical CDMO Evergreen Theragnostics in a deal worth up to $1 billion, expanding its manufacturing capabilities and drug pipeline. The acquisition includes Octevy, a ...
Lantheus Holdings Inc. is adding to its portfolio yet again, acquiring a clinical-stage radiopharmaceutical company in a deal ...
On a quest to carve out a spot as one of the nuclear medicine greats, Massachusetts-based radiopharmaceutical specialist ...
Well before market open that morning, Lantheus announced that it has signed a definitive agreement to acquire clinical-stage ...
Lantheus Holdings, Inc. (LNTH), a radiopharmaceutical company, experienced a 9% drop in its stock price on Tuesday after announcing a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback